152 related articles for article (PubMed ID: 16836930)
1. [Prognostic value of E-cadherin, CD34 in the patients with hepatocellular carcinoma].
Wu LQ; Lu Y; Lu HJ; Zhang B; Yang JY; Ma X
Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(11):774-7. PubMed ID: 16836930
[TBL] [Abstract][Full Text] [Related]
2. Relation among p130Cas, E-cadherin and beta-catenin expression, clinicopathologic significance and prognosis in human hepatocellular carcinoma.
Guo C; Liu QG; Yang W; Zhang ZL; Yao YM
Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):490-6. PubMed ID: 18842495
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma.
Korita PV; Wakai T; Shirai Y; Matsuda Y; Sakata J; Cui X; Ajioka Y; Hatakeyama K
Hum Pathol; 2008 Dec; 39(12):1777-83. PubMed ID: 18701136
[TBL] [Abstract][Full Text] [Related]
4. Expression of E- and N-cadherin and clinicopathology in hepatocellular carcinoma.
Cho SB; Lee KH; Lee JH; Park SY; Lee WS; Park CH; Kim HS; Choi SK; Rew JS
Pathol Int; 2008 Oct; 58(10):635-42. PubMed ID: 18801083
[TBL] [Abstract][Full Text] [Related]
5. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
Chen XJ; Wu LM; Xu XB; Feng XW; Xie HY; Zhang M; Shen Y; Wang WL; Liang TB; Zheng SS
Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1354-8. PubMed ID: 18241575
[TBL] [Abstract][Full Text] [Related]
6. Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma.
Ding ZB; Shi YH; Zhou J; Shi GM; Ke AW; Qiu SJ; Wang XY; Dai Z; Xu Y; Fan J
Cancer; 2009 Oct; 115(20):4753-65. PubMed ID: 19626651
[TBL] [Abstract][Full Text] [Related]
7. Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients.
Seo DD; Lee HC; Kim HJ; Min HJ; Kim KM; Lim YS; Chung YH; Lee YS; Suh DJ; Yu E; Chun SY
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1112-8. PubMed ID: 17944884
[TBL] [Abstract][Full Text] [Related]
8. [Expression patterns of E-cadherin and beta-catenin according to clinicopathological characteristics of hepatocellular carcinoma].
Bae SH; Jung ES; Park YM; Jang JW; Choi JY; Cho SH; Yoon SK; Ahn BM; Cha SB; Chung KW; Sun HS; Park DH; Kim BK; Kim DG
Taehan Kan Hakhoe Chi; 2002 Sep; 8(3):297-303. PubMed ID: 12499787
[TBL] [Abstract][Full Text] [Related]
9. Reduced N-cadherin expression is associated with metastatic potential and poor surgical outcomes of hepatocellular carcinoma.
Zhan DQ; Wei S; Liu C; Liang BY; Ji GB; Chen XP; Xiong M; Huang ZY
J Gastroenterol Hepatol; 2012 Jan; 27(1):173-80. PubMed ID: 21777276
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma.
Li XR; Ji F; Ouyang J; Wu W; Qian LY; Yang KY
Eur J Surg Oncol; 2006 Dec; 32(10):1130-4. PubMed ID: 16806792
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma.
Zhao WB; Li Y; Liu X; Zhang LY; Wang X
Int J Mol Med; 2008 Aug; 22(2):187-92. PubMed ID: 18636172
[TBL] [Abstract][Full Text] [Related]
12. Correlation of E-cadherin expression and recurrence of hepatocellular carcinoma.
Huang GT; Lee HS; Chen CH; Sheu JC; Chiou LL; Chen DS
Hepatogastroenterology; 1999; 46(27):1923-7. PubMed ID: 10430370
[TBL] [Abstract][Full Text] [Related]
13. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
Nakai S; Masaki T; Shiratori Y; Ohgi T; Morishita A; Kurokohchi K; Watanabe S; Kuriyama S
Int J Oncol; 2002 Apr; 20(4):769-75. PubMed ID: 11894123
[TBL] [Abstract][Full Text] [Related]
14. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma.
Higashi Y; Suzuki S; Sakaguchi T; Nakamura T; Baba S; Reinecker HC; Nakamura S; Konno H
J Surg Res; 2007 May; 139(1):68-76. PubMed ID: 17270214
[TBL] [Abstract][Full Text] [Related]
15. Cadherin/catenin complex appears to be intact in hepatocellular carcinomas from Australia and South Africa.
Herath NI; Walsh MD; Kew MC; Young J; Leggett BA; Macdonald GA
J Gastroenterol Hepatol; 2004 Jun; 19(6):676-82. PubMed ID: 15151624
[TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of VEGF and MMP-9 in hepatocellular carcinoma].
Zhong C; Guo RP; Shi M; Wei W; Yu WS; Li JQ
Ai Zheng; 2006 May; 25(5):599-603. PubMed ID: 16687082
[TBL] [Abstract][Full Text] [Related]
17. Can E-cadherin and CD34 be used as indicators of prognosis for hepatocellular carcinoma patients?
Wu LQ; Lu Y; Lu HJ; Lv ZH
Clin Chem Lab Med; 2008; 46(8):1122-6. PubMed ID: 18724809
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.
Lim SO; Gu JM; Kim MS; Kim HS; Park YN; Park CK; Cho JW; Park YM; Jung G
Gastroenterology; 2008 Dec; 135(6):2128-40, 2140.e1-8. PubMed ID: 18801366
[TBL] [Abstract][Full Text] [Related]
19. Expression of P-aPKC-iota, E-cadherin, and beta-catenin related to invasion and metastasis in hepatocellular carcinoma.
Du GS; Wang JM; Lu JX; Li Q; Ma CQ; Du JT; Zou SQ
Ann Surg Oncol; 2009 Jun; 16(6):1578-86. PubMed ID: 19290490
[TBL] [Abstract][Full Text] [Related]
20. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
Gao YW; Chen YX; Wang ZM; Zhou LD; Li XY; Li LX; Luo QZ; Tian W; Fu CY; Zhou JH
Hepatogastroenterology; 2008; 55(82-83):345-50. PubMed ID: 18613363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
